Trial Profile
Phase II Study of REGN2810 Prior to Surgery in Patients With Stage II-IV Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary)
- Indications Carcinoma; Head and neck cancer; Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- 13 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 13 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 27 Jul 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.